Axa
SAGE

Axa’s Sage Therapeutics SAGE Stock Holding History

Axa’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,600
Closed -$432K – 1309
2021
Q2 		$432K Sell
7,600
-30,319
-80% -$2.14M ﹤0.01% 1123
2021
Q1 		$2.84M Sell
37,919
-89,276
-70% -$7.32M 0.01% 797
2020
Q4 		$11M Sell
127,195
-2,182
-2% -$161K 0.03% 492
2020
Q3 		$7.91M Sell
129,377
-93,895
-42% -$4.76M 0.03% 524
2020
Q2 		$9.28M Buy
223,272
+178,821
+402% +$6.49M 0.04% 457
2020
Q1 		$1.28M Sell
44,451
-2,826
-6% -$164K 0.01% 816
2019
Q4 		$3.41M Buy
47,277
+1,080
+2% +$133K 0.01% 714
2019
Q3 		$6.48M Sell
46,197
-82
-0.2% -$13.7K 0.03% 573
2019
Q2 		$8.47M Buy
46,279
+1,009
+2% +$172K 0.03% 515
2019
Q1 		$7.2M Hold
45,270
– – 0.03% 541
2018
Q4 		$4.34M Sell
45,270
-24,300
-35% -$2.78M 0.02% 644
2018
Q3 		$9.83M Sell
69,570
-100
-0.1% -$15.4K 0.04% 485
2018
Q2 		$10.9M Buy
69,670
+6,676
+11% +$1.05M 0.04% 425
2018
Q1 		$10.1M Buy
62,994
+17,874
+40% +$3.03M 0.04% 440
2017
Q4 		$7.43M Sell
45,120
-1,344
-3% -$130K 0.03% 559
2017
Q3 		$2.9M Buy
46,464
+676
+1% +$53.1K 0.01% 752
2017
Q2 		$3.65M Sell
45,788
-1,721
-4% -$124K 0.02% 671
2017
Q1 		$3.38M Sell
47,509
-1,493
-3% -$87.5K 0.02% 673
2016
Q4 		$2.5M Buy
49,002
+927
+2% +$43.7K 0.01% 719
2016
Q3 		$2.21M Buy
48,075
+44
+0.1% +$1.79K 0.01% 736
2016
Q2 		$1.45M Buy
+48,031
New +$1.6M 0.01% 810

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Axa's SAGE Position: Q3 2021 in Review

Axa sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 7,600 shares — an estimated $432K sold.

Axa first reported a position in SAGE in Q2 2016 and held it in 21 quarters. The position peaked at $11M in Q4 2020. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Axa reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Axa sold 7,600 Sage Therapeutics shares in Q3 2021, an estimated $432K.
  • Axa first reported a position in Sage Therapeutics in Q2 2016 and held it in 21 quarters.
  • Axa's Sage Therapeutics position peaked at $11M in Q4 2020.
  • 226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.